KRAS and non-small cell lung carcinoma: As PDL1 expression is a predictive biomarker of ICI, this was the first reported systematic study to reveal the superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant NSCLC [51].